Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection.Tokyo, Japan, June 16, 2006 - (JCN) - Dainippon Sumitomo Pharma will release AmBisome 50mg for intravenous drip intravenous drip n. infusion, an antifungal The continuous introduction of a solution intravenously, a drop at a time. 1. destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections. 2. an agent that so acts. an·ti·fun·gal (  n agent for treating deep-seated mycosis mycosis fungoi´des a chronic, malignant, lymphoreticular neoplasm of the skin and, in late stages, lymph nodes and viscera, with development of large, painful, ulcerating tumors. my·co·sis (m  -k infection, on June 20. AmBiosome, which the company has licensed from US company Gilead Sciences, is a liposomal formulation of amphotericin B amphotericin B /am·pho·ter·i·cin B/ (-ter´i-sin) an antibiotic derived from strains of Streptomyces nodosus; effective against a wide range of fungi and some species of Leishmania. am·pho·ter·i·cin B (. It retains the efficacy of amphotericin B while reducing the damage to kidneys. AmBisome is the only antifungal agent indicated for the treatment of febrile febrile /feb·rile/ (feb´ril) pertaining to or characterized by fever. feb·rile (f  b r neutropenia neutropenia /neu·tro·pe·nia/ (noo?tro-pe´ne-ah) diminished number of neutrophils in the blood.neu·tro·pe·ni·a (n   tr with suspected mycotic 1. pertaining to mycosis. 2. caused by a fungus. my·cot·ic (m -k t infection. The agent is currently available in 45 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion